yervoy
bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml; - concentrate for injection - 200 mg/40 ml - active: ipilimumab 5 mg/ml excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.
yervoy
bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml; - concentrate for injection - 50 mg/10 ml - active: ipilimumab 5 mg/ml excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.
paclitaxel bristol-myers squibb 6 mg/ml, solution à diluer pour perfusion
bristol - myers squibb - paclitaxel - solution - 6 mg - composition pour 1 ml de solution à diluer pour perfusion > paclitaxel : 6 mg - taxanes
paracetamol codeine bristol-myers squibb 25 mg/1,495 mg/ml, suspension buvable
bristol - myers squibb - paracétamol - suspension - 2,5 g - composition pour 100 ml > paracétamol : 2,5 g > codéine : 0,1495 g . sous forme de : codéine (phosphate de) hémihydraté 0,2036 g - analgésiques
paracetamol codeine bristol-myers squibb 12 mg/0,6 mg/ml, suspension buvable
bristol - myers squibb - paracétamol - suspension - 1,2 g - composition pour 100 ml > paracétamol : 1,2 g > codéine : 0,06 g . sous forme de : codéine (phosphate de) hémihydraté 0,0815 g - analgésiques
xenon [133 xe] 925 mbq bristol myers squibb, gaz pour inhalation en flacon [réf : xe-133-gv-5 (925 mbq)]
bristol myers squibb pharma belgium sprl - xénon [133 xe] (gaz) - gaz - 925 mbq à la date de calibration - composition pour un flacon > xénon [133 xe] (gaz) : 925 mbq à la date de calibration - produit radiopharmaceutique à usage diagnostique
opdivo
bristol-myers squibb (nz) limited - nivolumab 10 mg/ml; ; ; - concentrate for infusion - 100 mg/10ml - active: nivolumab 10 mg/ml excipient: hydrochloric acid mannitol pentetic acid polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - opdivo, as monotherapy is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, in combination with yervoy (ipilimumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, as monotherapy, is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
opdivo
bristol-myers squibb (nz) limited - nivolumab 10 mg/ml; ; ; - concentrate for infusion - 40 mg/4ml - active: nivolumab 10 mg/ml excipient: hydrochloric acid mannitol pentetic acid polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - opdivo, as monotherapy is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, in combination with yervoy (ipilimumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, as monotherapy, is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
daklinza
bristol-myers squibb (nz) limited - daclatasvir dihydrochloride 33mg equivalent to daclatasvir 30mg - tablet - 30 mg - active: daclatasvir dihydrochloride 33mg equivalent to daclatasvir 30mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis).
daklinza
bristol-myers squibb (nz) limited - daclatasvir dihydrochloride 66mg equivalent to daclatasvir 60mg - tablet - 60 mg - active: daclatasvir dihydrochloride 66mg equivalent to daclatasvir 60mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis).